CRISPR

CRISPR1-atp7a

ID
ZDB-CRISPR-200520-1
Name
CRISPR1-atp7a
Previous Names
None
Target
Sequence
5' - GGCCGGATCGGAGGCCTGCC - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
The PAM site was AGG at the 3' end.
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
hza4 atp7a
Expression
Gene expression in Wild Types + CRISPR1-atp7a
No data available
Phenotype
Phenotype resulting from CRISPR1-atp7a
No data available
Phenotype of all Fish created by or utilizing CRISPR1-atp7a
Phenotype Fish Conditions Figures
intestine hspa5 expression increased amount, abnormal atp7ahza4/hza4 control Fig. 6 from Zhao et al., 2019
intestinal epithelial cell mitochondrial inner membrane swollen, abnormal atp7ahza4/hza4 control Fig. 6 from Zhao et al., 2019
whole organism cox4i2 expression increased amount, abnormal atp7ahza4/hza4 control Fig. 7 with image from Zhao et al., 2020
whole organism eif2ak3 expression increased amount, abnormal atp7ahza4/hza4 control Fig. 7 with image from Zhao et al., 2020
whole organism fabp2 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 6 from Zhao et al., 2019
whole organism hmox2a expression increased amount, abnormal atp7ahza4/hza4 control Fig. 7 with image from Zhao et al., 2020
intestine slc15a1b expression decreased amount, abnormal atp7ahza4/hza4 control Fig. 6 from Zhao et al., 2019
intestine fabp2 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 6 from Zhao et al., 2019
retina opn1sw1 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
retina opn1sw1 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
whole organism eif2ak3 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
whole organism ern1 expression increased amount, abnormal atp7ahza4/hza4 control Fig. 7 with image from Zhao et al., 2020
whole organism cox4i2 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
retina mitochondrion swollen, abnormal atp7ahza4/hza4 standard conditions Fig. 7 with image from Zhao et al., 2020
whole organism cyp8b1.1 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 6 from Zhao et al., 2019
whole organism ern1 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
brain hspa5 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
whole organism hmox2a expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
whole organism rho expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
whole organism slc15a1b expression decreased amount, abnormal atp7ahza4/hza4 control Fig. 6 from Zhao et al., 2019
brain ddit3 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
whole organism opn1sw1 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
whole organism znrf2a expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
whole organism cyp3a65 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 6 from Zhao et al., 2019
whole organism opn1sw2 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
intestine fabp2 expression decreased amount, abnormal atp7ahza4/hza4 control Fig. 6 from Zhao et al., 2019
brain hspa5 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
whole organism loxa expression increased amount, abnormal atp7ahza4/hza4 control Fig. 7 with image from Zhao et al., 2020
whole organism opn1sw2 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
whole organism ern1 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
whole organism eif2ak3 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
whole organism opn1sw1 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
whole organism slc15a1b expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 6 from Zhao et al., 2019
intestinal epithelial cell endoplasmic reticulum structure, exacerbated atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 6 from Zhao et al., 2019
whole organism rho expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
intestine hspa5 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 6 from Zhao et al., 2019
intestinal epithelial cell endoplasmic reticulum structure, exacerbated atp7ahza4/hza4 chemical treatment: copper atom Fig. 6 from Zhao et al., 2019
whole organism znrf2a expression increased amount, abnormal atp7ahza4/hza4 control Fig. 7 with image from Zhao et al., 2020
whole organism atf6 expression increased amount, abnormal atp7ahza4/hza4 control Fig. 7 with image from Zhao et al., 2020
whole organism hmox2a expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
brain ddit3 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
whole organism cyp3a65 expression decreased amount, abnormal atp7ahza4/hza4 control Fig. 6 from Zhao et al., 2019
whole organism loxa expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
retina mitochondrion swollen, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
intestinal epithelial cell mitochondrial inner membrane swollen, exacerbated atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 6 from Zhao et al., 2019
whole organism znrf2a expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
retina opn1sw2 expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. S8 from Zhao et al., 2020
retina mitochondrion swollen, abnormal atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
whole organism cox4i2 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
whole organism cyp8b1.1 expression decreased amount, abnormal atp7ahza4/hza4 control Fig. 6 from Zhao et al., 2019
whole organism atf6 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper atom Fig. 7 with image from Zhao et al., 2020
intestinal epithelial cell mitochondrial inner membrane swollen, exacerbated atp7ahza4/hza4 chemical treatment: copper atom Fig. 6 from Zhao et al., 2019
whole organism fabp2 expression decreased amount, abnormal atp7ahza4/hza4 control Fig. 6 from Zhao et al., 2019
whole organism atf6 expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
intestinal epithelial cell endoplasmic reticulum loose, abnormal atp7ahza4/hza4 control Fig. 6 from Zhao et al., 2019
whole organism loxa expression amount, ameliorated atp7ahza4/hza4 chemical treatment: copper(2+) Fig. 7 with image from Zhao et al., 2020
intestine slc15a1b expression decreased amount, abnormal atp7ahza4/hza4 chemical treatment: copper atom Fig. 6 from Zhao et al., 2019
whole organism Ab3-gpx4 labeling amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: ferrostatin-1 Fig. 4 with image from Wu et al., 2025
whole organism tfr1a expression decreased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 2 with image from Wu et al., 2025
spinal cord myelin sheath decreased thickness, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 1 with image from Wu et al., 2025
whole organism malonaldehyde amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: desferrioxamine B Fig. 5 with image from Wu et al., 2025
central nervous system myelin sheath mbpa expression decreased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 1 with image,  Fig. 4 with image,  Fig. 5 with image from Wu et al., 2025
whole organism Ab3-gpx4 labeling amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: desferrioxamine B Fig. 5 with image from Wu et al., 2025
whole organism fth1a expression decreased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 2 with image from Wu et al., 2025
central nervous system myelin sheath plp1a expression amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: desferrioxamine B Fig. 5 with image from Wu et al., 2025
whole organism Ab3-gpx4 labeling decreased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 3 with image,  Fig. 4 with image,  Fig. 5 with image from Wu et al., 2025
whole organism malonaldehyde amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: ferrostatin-1 Fig. 4 with image from Wu et al., 2025
spinal cord membrane lipid catabolic process increased occurrence, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 3 with image from Wu et al., 2025
whole organism membrane lipid catabolic process occurrence, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: ferrostatin-1 Fig. 4 with image from Wu et al., 2025
central nervous system myelin sheath plp1a expression decreased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 1 with image,  Fig. 4 with image,  Fig. 5 with image from Wu et al., 2025
whole organism iron atom increased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 2 with image from Wu et al., 2025
central nervous system glioblast (sensu Vertebrata) tfr1a expression decreased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 2 with image from Wu et al., 2025
whole organism Ab3-gpx4 labeling amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: ammonium chloride Fig. 4 with image from Wu et al., 2025
central nervous system myelin sheath mbpa expression amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: ferrostatin-1 Fig. 4 with image from Wu et al., 2025
neuron regulation of membrane potential disrupted, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 1 with image from Wu et al., 2025
spinal cord myelin sheath decondensed, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 1 with image from Wu et al., 2025
whole organism malonaldehyde increased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 4 with image,  Fig. 5 with image from Wu et al., 2025
central nervous system myelin sheath mbpa expression amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: desferrioxamine B Fig. 5 with image from Wu et al., 2025
head Ab3-gpx4 labeling decreased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 3 with image from Wu et al., 2025
central nervous system neuronal stem cell sox2 expression decreased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 1 with image from Wu et al., 2025
central nervous system myelin sheath plp1a expression amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: copper(II) sulfate, chemical treatment by environment: elesclomol Fig. 1 with image from Wu et al., 2025
central nervous system myelin sheath mbpa expression amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: copper(II) sulfate, chemical treatment by environment: elesclomol Fig. 1 with image from Wu et al., 2025
central nervous system myelin sheath plp1a expression amount, ameliorated atp7ahza4/hza4 (AB) chemical treatment by environment: ferrostatin-1 Fig. 4 with image from Wu et al., 2025
whole organism membrane lipid catabolic process increased occurrence, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 4 with image from Wu et al., 2025
central nervous system glioblast (sensu Vertebrata) olig2 expression decreased amount, abnormal atp7ahza4/hza4 (AB) standard conditions Fig. 1 with image from Wu et al., 2025
central nervous system axon extension decreased rate of occurrence, abnormal atp7ahza4/hza4; vu19Tg (AB) standard conditions Fig. 1 with image from Wu et al., 2025
central nervous system glioblast (sensu Vertebrata) Ab3-gpx4 labeling amount, ameliorated atp7ahza4/hza4; vu19Tg (AB) chemical treatment by environment: desferrioxamine B Fig. 5 with image from Wu et al., 2025
central nervous system collateral sprouting decreased occurrence, abnormal atp7ahza4/hza4; vu19Tg (AB) standard conditions Fig. 1 with image from Wu et al., 2025
central nervous system glioblast (sensu Vertebrata) Ab3-gpx4 labeling decreased amount, abnormal atp7ahza4/hza4; vu19Tg (AB) standard conditions Fig. 3 with image,  Fig. 4 with image,  Fig. 5 with image from Wu et al., 2025
central nervous system axon decreased length, abnormal atp7ahza4/hza4; vu19Tg (AB) standard conditions Fig. 1 with image from Wu et al., 2025
spinal cord apoptotic process increased occurrence, abnormal atp7ahza4/hza4; vu19Tg (AB) standard conditions Fig. 3 with image from Wu et al., 2025
central nervous system DsRed2 expression decreased amount, abnormal atp7ahza4/hza4; vu19Tg (AB) standard conditions Fig. 1 with image from Wu et al., 2025
central nervous system glioblast (sensu Vertebrata) Ab3-gpx4 labeling amount, ameliorated atp7ahza4/hza4; vu19Tg (AB) chemical treatment by environment: ferrostatin-1 Fig. 4 with image from Wu et al., 2025
central nervous system axon decreased branchiness, abnormal atp7ahza4/hza4; vu19Tg (AB) standard conditions Fig. 1 with image from Wu et al., 2025
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.